Spironolactone, Anesthesia, and Surgery: What Every Woman Needs to Know Before Going Under

Why the Operating Room and Spironolactone Are an Uncomfortable Combination

Spironolactone works by blocking aldosterone receptors in the kidney, which causes sodium loss and potassium retention. That mechanism, perfectly useful for clearing hormonal acne or managing PCOS-related androgen excess, becomes a liability when you add the cardiovascular and electrolyte stresses of surgery and anesthesia.

Aldosterone blockade by spironolactone is well-characterized at the renal tubule, and its downstream effects on serum potassium and blood pressure are dose-dependent. At the 50 to 200 mg/day doses commonly prescribed for acne and PCOS, the drug consistently raises serum potassium by 0.1 to 0.3 mEq/L in otherwise healthy young women. That shift sounds small. In an operating room where anesthetic agents also affect cardiac conduction, it is not small at all.

Three mechanisms converge to create perioperative risk.

Mechanism 1: Potassium Accumulation and Cardiac Conduction

Spironolactone reduces potassium excretion. Hyperkalemia, defined as serum potassium above 5.0 mEq/L, prolongs the PR interval, widens the QRS complex, and can trigger ventricular arrhythmia. General anesthetic agents including propofol, volatile halogenated gases (sevoflurane, desflurane), and succinylcholine all affect myocardial conduction independently. Succinylcholine is particularly relevant: it is a depolarizing neuromuscular blocker that routinely raises serum potassium by 0.5 to 1.0 mEq/L on its own. In a patient whose baseline potassium is already elevated because of spironolactone, that additive rise can push levels into a dangerous range.

Mechanism 2: Vasodilation and Hypotension Under Anesthesia

Spironolactone lowers blood pressure through natriuresis (sodium and water loss) and direct vascular effects. General and neuraxial (spinal or epidural) anesthesia independently cause vasodilation and blood pressure drops. When you combine the two, intraoperative hypotension is more likely and harder to correct. Intraoperative hypotension is associated with myocardial injury, acute kidney injury, and 30-day mortality in surgical patients. Anesthesiologists account for this by adjusting induction agents and vasopressor thresholds, but they can only do that if they know you are on spironolactone.

Mechanism 3: Fluid and Volume Shifts

Aldosterone normally promotes sodium and water reabsorption. Blocking it with spironolactone means your circulating blood volume may be lower than expected for your weight. Surgical fluid management calculations depend on estimated volume status. A patient who is running mildly volume-depleted from spironolactone responds differently to intraoperative fluid boluses, vasopressors, and blood loss than the textbook patient.

How Long Before Surgery Should You Stop Spironolactone?

There is no single universal answer, and that reflects a genuine gap in prospective trial data in women specifically. Most published anesthesia guidelines recommend holding aldosterone antagonists for one to seven days before elective procedures.

The American Society of Anesthesiologists (ASA) preoperative medication guidance advises individualized decision-making for potassium-sparing diuretics, and the ACC/AHA perioperative cardiovascular evaluation guidelines recommend withholding diuretics on the morning of surgery for non-cardiac procedures when volume depletion is a concern. The specific hold duration for spironolactone depends on:

• Your dose. Women taking 100 to 200 mg/day for acne carry more aldosterone-blockade than someone on 25 mg/day for mild PCOS. Higher doses warrant a longer hold.
• Your baseline potassium. If your most recent potassium is above 4.5 mEq/L, most anesthesiologists want at least three to five days of drug-free time to allow renal clearance.
• Your blood pressure. If spironolactone is your primary antihypertensive, stopping it entirely may not be safe. Your prescribing clinician and anesthesiologist need to coordinate.
• Surgical duration and type. A 10-minute dermatology procedure under local anesthesia carries different stakes than a three-hour laparoscopic gynaecologic surgery under general anesthesia.

A practical decision framework for women on spironolactone before surgery:

| Scenario | Suggested action | |---|---| | Acne or PCOS, dose 25-100 mg/day, potassium normal, elective surgery | Hold 2-3 days pre-op; recheck potassium if >4.5 mEq/L at last draw | | Acne or PCOS, dose 100-200 mg/day, elective surgery | Hold 5-7 days pre-op; get potassium level within 7 days of surgery | | Primary hypertension, spironolactone as only antihypertensive | Do NOT hold without cardiology or prescriber input; coordinate care | | Emergency surgery | Alert anesthesia team immediately; continuous cardiac monitoring, avoid succinylcholine if alternatives exist | | Procedure under local anesthesia only, no sedation | Continue spironolactone; monitor for dizziness post-procedure |

These ranges align with published perioperative pharmacology reviews, though direct randomized trial data specifically in women is thin. The evidence is largely extrapolated from heart failure populations (where spironolactone was studied in RALES and EPHESUS) combined with general anesthesia pharmacology principles.

What Spironolactone Does in Women Specifically: The Hormonal Picture

Spironolactone is used far more often in women than men, and almost entirely for sex-specific indications. That matters for understanding why its interactions with anesthesia deserve a women-specific explanation.

Reproductive-Age Women (Ages 18-40): Acne and PCOS

In women of reproductive age, spironolactone 50 to 200 mg/day reduces androgenic acne through dual blockade of androgen receptors and andosterone synthesis. A 2023 randomized trial published in the BMJ (the SAFA trial) showed that spironolactone 50-200 mg/day significantly reduced acne lesion count versus placebo over 24 weeks, confirming what dermatologists had used off-label for decades.

In PCOS, spironolactone addresses hyperandrogenism when first-line oral contraceptives are insufficient or not wanted. ACOG Practice Bulletin 194 on PCOS acknowledges spironolactone as a reasonable adjunct for hirsutism and acne in women who decline or cannot tolerate hormonal contraception.

Women in this life stage who schedule elective procedures (think: gynecologic surgeries, breast procedures, rhinoplasty, laparoscopy for endometriosis) are the most likely to be on spironolactone for acne or PCOS. They are also the most likely to forget to mention it to their surgical team because they think of it as "an acne pill," not a cardiovascular drug.

Perimenopause (Ages 40-55): The Dual-Role Phase

In perimenopause, spironolactone may serve double duty: managing late-onset acne driven by falling estrogen and rising androgen ratios, while also helping blood pressure that begins to rise as estrogen's vascular-protective effects wane. Perimenopausal women frequently carry more comorbidities than their younger counterparts, meaning their baseline potassium and renal function deserve closer scrutiny before surgery.

Postmenopause: Blood Pressure and Heart Failure Context

In postmenopausal women, spironolactone is less often a dermatology drug and more often a cardiovascular one. The RALES trial showed spironolactone 25 mg/day reduced all-cause mortality by 30% in severe heart failure, a population that is heavily postmenopausal women. In this group, stopping spironolactone before surgery requires cardiology coordination, not a simple hold.

Spironolactone and Alcohol: A Separate but Real Risk

The question "can I drink on spironolactone?" comes up constantly, and the answer is nuanced rather than a flat no.

Spironolactone causes vasodilation and blood pressure reduction. Alcohol does the same. Combined, they produce additive hypotension, which in practical terms means dizziness, lightheadedness, and a real fall risk, especially in women who are also taking oral contraceptives or other antihypertensives. Alcohol-induced hypotension is mediated partly through vasodilatory prostaglandins and reduced sympathetic tone, mechanisms that stack directly on top of spironolactone's aldosterone blockade.

In a preoperative context, alcohol matters for an additional reason. Women who drink alcohol regularly may have altered hepatic metabolism, affecting how quickly spironolactone and its active metabolite canrenone are cleared. Spironolactone is extensively metabolized in the liver to canrenone, which accounts for a significant portion of its biological activity. Impaired hepatic function extends the effective drug half-life, meaning a standard two-day hold may not be enough.

Practical guidance:

• Avoid alcohol for at least 48 hours before any surgical procedure, regardless of spironolactone use.
• If you drink regularly (more than seven drinks per week), tell your anesthesiologist. This affects both drug clearance and anesthetic dosing.
• Social drinking of one or two drinks on spironolactone is not dangerous for most women, but watch for dizziness, especially when standing.

Specific Drug-Drug Interactions in the Perioperative Setting

Beyond anesthesia itself, the operating room introduces a predictable set of co-medications. Here is where spironolactone's interactions become very concrete.

NSAIDs and Ketorolac

Ketorolac (Toradol) is the most commonly used intraoperative and immediately postoperative NSAID for pain management. NSAIDs reduce prostaglandin-mediated renal blood flow, which can acutely blunt spironolactone's diuretic and antihypertensive efficacy and, paradoxically, worsen potassium retention by reducing tubular flow. The combination raises the risk of acute kidney injury and hyperkalemia in the postoperative period.

ACE Inhibitors and ARBs

Many women on spironolactone for blood pressure or heart failure are also on an ACE inhibitor (lisinopril, enalapril) or ARB (losartan, valsartan). Concurrent use of spironolactone with an ACE inhibitor or ARB significantly raises the risk of hyperkalemia. Perioperatively, when renal perfusion is already under stress, this triple threat (spironolactone + ACE inhibitor or ARB + surgical stress) deserves explicit pre-anesthesia potassium monitoring.

Vasopressors

If intraoperative hypotension occurs and requires vasopressor support (phenylephrine, norepinephrine, ephedrine), patients on spironolactone may need higher doses or different agents. This is not a contraindication to vasopressors, but it changes the expected dose-response and should be on the anesthesiologist's radar.

Succinylcholine

As described above, succinylcholine raises serum potassium by 0.5 to 1.0 mEq/L within minutes of administration. In a patient on spironolactone whose potassium is already at 5.0 mEq/L, this risks pushing into the 5.5 to 6.0 mEq/L range where cardiac dysrhythmia risk rises sharply. Rocuronium (reversed with sugammadex) is a non-depolarizing alternative that does not cause potassium release and is preferred when hyperkalemia risk is elevated.

Pregnancy, Lactation, and Contraception: Required Reading

Spironolactone is contraindicated in pregnancy. This is not a precautionary caution; it is a firm contraindication based on animal data showing feminization of male fetuses and theoretical anti-androgenic effects on fetal genital development.

The FDA labels spironolactone as Pregnancy Category C/D (old system) with a warning that its anti-androgenic metabolites cross the placenta. Because spironolactone can cause feminization of a male fetus during organogenesis, any woman of reproductive age taking it must use reliable contraception. ACOG and dermatology consensus guidelines recommend concurrent use of an effective contraceptive method while on spironolactone.

In practical terms, this creates an interesting surgical consideration: women on spironolactone are often also on oral contraceptives. Combined oral contraceptives that contain an estrogen component can raise potassium in women on spironolactone by reducing aldosterone-mediated potassium excretion, particularly with the progestin drospirenone, which itself has mild aldosterone-blocking activity. Drospirenone-containing pills (Yasmin, Yaz) combined with spironolactone theoretically compound hyperkalemia risk, which is worth flagging in the preoperative medication review.

Lactation: Spironolactone is transferred into breast milk in small amounts. Available data suggest canrenone concentrations in breast milk are low, and short-term use may be compatible with breastfeeding, but long-term safety data in breastfed infants is absent. Postpartum women considering spironolactone for postpartum acne or hair loss should discuss the risk-benefit with their provider.

If you discover you are pregnant while taking spironolactone: Stop the drug and contact your OB-GYN or midwife immediately. A single short-term exposure before confirmed pregnancy is unlikely to cause harm, but continued use into organogenesis (weeks 4 to 10) carries fetal risk.

Who This Is Right For and Who Should Be Cautious

Women Who Can Typically Continue Spironolactone Until the Perioperative Hold Window

• Healthy reproductive-age women on 25 to 100 mg/day for acne or PCOS with normal potassium (<4.5 mEq/L) and normal blood pressure
• Women undergoing procedures under local anesthesia with no IV sedation
• Women having minor outpatient procedures with an anesthesia team that has been informed

Women Who Need Closer Pre-Anesthesia Coordination

• Any woman on spironolactone plus an ACE inhibitor, ARB, or drospirenone-containing OCP
• Women with CKD stage 3 or above (reduced renal clearance means potassium accumulates faster)
• Perimenopausal or postmenopausal women with baseline hypertension, where stopping spironolactone could destabilize blood pressure
• Women with a recent potassium above 4.8 mEq/L
• Women on high doses (150 to 200 mg/day)

Women Who Should Not Stop Without a Specialist's Input

• Women taking spironolactone for heart failure (NYHA class III or IV), where the RALES trial data showed mortality benefit from continued use
• Women with primary hyperaldosteronism (Conn syndrome), where stopping the drug allows aldosterone-driven hypertension to rebound rapidly

What to Actually Tell Your Surgical Team

Clear, specific communication prevents most perioperative spironolactone complications. Use this checklist.

1. Tell your surgeon's office at the time of scheduling that you take spironolactone, your dose, and your indication.
2. Request a preoperative electrolyte panel (basic metabolic panel or at minimum serum potassium) within seven days of surgery.
3. At your pre-anesthesia visit or phone screen, confirm the hold plan with the anesthesiologist directly. Ask specifically: "Do you want me to hold spironolactone, and for how many days?"
4. If you are also on an ACE inhibitor, ARB, or drospirenone-containing pill, name all three drugs explicitly.
5. On the day of surgery, bring your medication list including dose and frequency.
6. In the recovery room, ask when you should restart spironolactone. Most providers restart it within 24 to 48 hours after surgery once oral intake and renal function are confirmed.

As WomanRx advisor and OB-GYN Dr. Rachel Goldberg notes: "Women almost never mention spironolactone to their surgical team because they categorize it mentally as a skin drug, not a heart drug. That disconnect is where the perioperative risk lives. The anesthesiologist needs to know, every time, without exception."

The Evidence Gap: What We Do and Don't Know in Women

Women are under-represented in the pharmacology literature on perioperative drug management. Most of the data underlying recommendations for holding aldosterone antagonists before surgery comes from heart failure trials (RALES, EPHESUS) in mixed-sex populations that were not powered to analyze sex-specific electrolyte responses, or from general anesthesia pharmacology studies that used male-predominant samples.

The RALES trial enrolled patients who were 73% male, and EPHESUS enrolled 71% male patients. Extrapolating hold windows, potassium thresholds, and vasopressor requirements from those datasets to a 28-year-old woman on 100 mg/day of spironolactone for acne involves meaningful uncertainty. The physiological differences are real: women have lower average muscle mass (affecting potassium distribution), lower average glomerular filtration rate adjusted for body size, and different aldosterone-renin ratios across the menstrual cycle.

Serum aldosterone is higher in the luteal phase of the menstrual cycle than in the follicular phase, which means spironolactone's potassium-raising effect may be blunted in the luteal phase and more pronounced in the follicular phase when aldosterone is lower and the drug's relative blockade is greater. No perioperative study has evaluated whether menstrual cycle timing at the time of surgery changes the risk profile. That is a data gap your anesthesiologist cannot fill, but you can flag your cycle timing in your intake information.

What is directly studied: the cardiovascular pharmacology of spironolactone, the electrolyte effects of aldosterone blockade, and the anesthetic pharmacology of agents used in the OR. The application to healthy young women on spironolactone for acne is carefully reasoned extrapolation, not a clean evidence base. Honest care means saying so.